{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T19:08:01Z","timestamp":1772392081116,"version":"3.50.1"},"reference-count":35,"publisher":"Informa UK Limited","issue":"8","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"published-print":{"date-parts":[[2024,8,2]]},"DOI":"10.1080\/17425255.2024.2373108","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T08:22:47Z","timestamp":1719476567000},"page":"841-855","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Overview of preclinical and clinical studies investigating pharmacokinetics and drug\u2013drug interactions of padsevonil"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2222-9813","authenticated-orcid":false,"given":"Hugues","family":"Chanteux","sequence":"first","affiliation":[{"name":"UCB Pharma","place":["Braine-l\u2019Alleud, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merran","family":"MacPherson","sequence":"additional","affiliation":[{"name":"UCB Pharma","place":["Slough, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hester","family":"Kramer","sequence":"additional","affiliation":[{"name":"UCB Pharma","place":["Braine-l\u2019Alleud, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Otoul","sequence":"additional","affiliation":[{"name":"UCB Pharma","place":["Braine-l\u2019Alleud, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Okagaki","sequence":"additional","affiliation":[{"name":"UCB Pharma","place":["Tokyo, Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Rospo","sequence":"additional","affiliation":[{"name":"UCB Pharma","place":["Braine-l\u2019Alleud, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"De Bruyn","sequence":"additional","affiliation":[{"name":"UCB Pharma","place":["Braine-l\u2019Alleud, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6855-6222","authenticated-orcid":false,"given":"Mark","family":"Watling","sequence":"additional","affiliation":[{"name":"UCB Pharma","place":["Brussels, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Bani","sequence":"additional","affiliation":[{"name":"UCB Pharma","place":["Braine-l\u2019Alleud, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Sciberras","sequence":"additional","affiliation":[{"name":"UCB Pharma","place":["Braine-l\u2019Alleud, Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"e_1_3_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14596"},{"key":"e_1_3_10_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011839"},{"key":"e_1_3_10_5_1","unstructured":"National Institute for Health and Care Excellence. NICE guideline [NG217]: epilepsies in children young people and adults. London: National Institute for Health and Care Excellence; 2022 [cited 2024 Apr 10]. Available from: https:\/\/www.nice.org.uk\/guidance\/ng217"},{"key":"e_1_3_10_6_1","doi-asserted-by":"publisher","DOI":"10.5698\/1535-7597.18.4.269"},{"key":"e_1_3_10_7_1","doi-asserted-by":"publisher","DOI":"10.5698\/1535-7597.18.4.260"},{"key":"e_1_3_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-012-0070-9"},{"key":"e_1_3_10_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182563b19"},{"key":"e_1_3_10_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00712"},{"key":"e_1_3_10_11_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.261149"},{"key":"e_1_3_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16497"},{"key":"e_1_3_10_13_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.261222"},{"key":"e_1_3_10_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.020446"},{"key":"e_1_3_10_15_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.044602"},{"key":"e_1_3_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01204-4"},{"key":"e_1_3_10_17_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.124.001660"},{"key":"e_1_3_10_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012514"},{"key":"e_1_3_10_19_1","doi-asserted-by":"publisher","DOI":"10.2174\/157015910792246254"},{"key":"e_1_3_10_20_1","unstructured":"Chanteux H Chapy H Van Asperen J et al. No impact of P-glycoprotein on the brain distribution of padsevonil. 2018 [cited 2024 Feb 14]. Available from: https:\/\/aesnet.org\/abstractslisting\/no-impact-of-p-glycoprotein-on-the-brain-distribution-of-padsevonil"},{"key":"e_1_3_10_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/epi4.12656"},{"key":"e_1_3_10_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcaa183"},{"key":"e_1_3_10_23_1","unstructured":"U.S. Food and Drug Administration. In vitro metabolism- and transporter-mediated drug-drug interaction studies - guidance for industry - draft guidance. 2017 [cited 2022 Jun 21]. Available from: https:\/\/www.fda.gov\/files\/drugs\/published\/In-Vitro-Metabolism\u2013and-Transporter\u2013Mediated-Drug-Drug-Interaction-Studies-Guidance-for-Industry.pdf"},{"key":"e_1_3_10_24_1","unstructured":"European Medicines Agency. Guideline on the investigation of drug interactions. 2012 [cited 2022 Jun 20]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf"},{"key":"e_1_3_10_25_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2001.01474.x"},{"key":"e_1_3_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12750"},{"key":"e_1_3_10_27_1","unstructured":"Otoul C Watling M Tytgat D et al. Padsevonil single and multiple rising dose safety tolerability pharmacokinetics and pharmacodynamics in healthy volunteers. 2017 [cited 2022 Jun 20]. Available from: https:\/\/cms.aesnet.org\/abstractslisting\/padsevonil-single-and-multiple-rising-dose-safety\u2013tolerability\u2013pharmacokinetics\u2013and-pharmacodynamics-in-healthy-volunteers"},{"key":"e_1_3_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12499"},{"key":"e_1_3_10_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.195"},{"key":"e_1_3_10_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000983"},{"key":"e_1_3_10_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00907-w"},{"key":"e_1_3_10_32_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.117.075481"},{"key":"e_1_3_10_33_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.021907"},{"key":"e_1_3_10_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-022-03274-2"},{"key":"e_1_3_10_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1767"},{"key":"e_1_3_10_36_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.0c00903"},{"key":"e_1_3_10_37_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2014.0714"}],"container-title":["Expert Opinion on Drug Metabolism & Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425255.2024.2373108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T09:48:23Z","timestamp":1750326503000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425255.2024.2373108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,2]]}},"alternative-id":["10.1080\/17425255.2024.2373108"],"URL":"https:\/\/doi.org\/10.1080\/17425255.2024.2373108","relation":{},"ISSN":["1742-5255","1744-7607"],"issn-type":[{"value":"1742-5255","type":"print"},{"value":"1744-7607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-04-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}